Skip to main content
芭薇股份 logo

芭薇股份 — Investor Relations & Filings

Ticker · 920123 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 240 across all filing types
Latest filing 2024-05-30 Regulatory Filings
Country CN China
Listing Beijing Stock Exchange 920123

About 芭薇股份

https://www.gzbawei.com/

Guangdong Bawei Biotechnology Corp., Ltd. is a comprehensive beauty and personal care solution provider specializing in research, development, production, and testing. The company offers integrated OEM, ODM, and OBM services, covering a wide range of product categories including skincare, hair care, body care, and makeup. Bawei is recognized for its commitment to scientific innovation, operating advanced R&D laboratories and an independent third-party testing center that ensures product safety and efficacy. By leveraging automated production lines and a rigorous quality management system, the company serves a diverse portfolio of domestic and international brands. Its core focus remains on delivering high-quality, customized formulations and manufacturing excellence to meet evolving consumer demands in the global beauty market.

Recent filings

Filing Released Lang Actions
第三届监事会第十八次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of Guangdong Bawei Biotechnology Co., Ltd. It details the meeting date, attendance, and the approval of proposals related to the use and adjustment of raised funds. The document is an official announcement of meeting resolutions rather than a full financial report or detailed management discussion. It does not contain financial statements or detailed financial analysis. It also references other announcements for detailed information. The document length is short (1424 characters) and it serves as a formal meeting resolution announcement. This fits best under Regulatory Filings (RNS) as it is a regulatory announcement about board resolutions and fund usage, not a full report or presentation.
2024-05-30 Chinese
万联证券股份有限公司关于广东芭薇生物科技股份有限公司使用募集资金置换预先已投入募投项目及已支付发行费用的自筹资金的核查意见
Regulatory Filings
2024-05-30 Chinese
湖南启元律师事务所关于广东芭薇生物科技股份有限公司2023年年度股东大会的法律意见书
Regulatory Filings
2024-05-20 Chinese
公司章程
Governance Information Classification · 100% confidence The document is titled as the Articles of Association (章程) of Guangdong Bawei Biotechnology Co., Ltd. It contains detailed provisions about the company's organization, shareholder rights, share issuance, share transfer restrictions, shareholder meetings, and governance structure. It references relevant laws and stock exchange rules, including the Beijing Stock Exchange and China Securities Regulatory Commission approvals. The content is a comprehensive governance document outlining the company's internal rules and shareholder relations rather than a financial report, announcement, or other filing types. Therefore, it fits the category of Governance Information (CGR). The document length is substantial and contains detailed governance provisions, not just an announcement or summary, confirming it is the governance document itself.
2024-05-20 Chinese
2023年年度股东大会决议公告
AGM Information Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 2023 Annual General Meeting (AGM) of Guangdong Bawei Biotechnology Co., Ltd. It includes information about the meeting date, attendance, voting results on various proposals including the annual report, board reports, financial reports, remuneration plans, and governance changes. The document references the 2023 annual report and other related disclosures but does not contain the full annual report itself. The content is focused on the AGM proceedings and voting outcomes rather than the full financial or management reports. Therefore, this document fits the category of AGM Information (AGM-R). The document length (8421 characters) and detailed meeting content support this classification with high confidence.
2024-05-20 Chinese
投资者关系活动记录表
Call Transcript Classification · 95% confidence The document is titled as an "投资者关系活动记录表" which translates to "Investor Relations Activity Record." It details an investor relations event held on May 16, 2024, specifically a "业绩说明会" or "Performance Explanation Meeting" related to the company's 2023 annual report. The content includes Q&A about the company's 2023 financial performance, business segments, patents, development plans, dividend policy, competitive advantages, and market outlook. The document is a transcript or summary of an earnings presentation and interactive session with investors, not the official annual report itself. It is also relatively short (3366 characters) and focuses on explaining the 2023 annual results and answering investor questions, which aligns with the definition of a Call Transcript (CT) or Earnings Release (ER). However, since it is a detailed Q&A session with investors about the annual results, it fits best as a Call Transcript (CT) rather than a brief Earnings Release (ER) which typically contains only key highlights. Therefore, the document is classified as a Call Transcript (CT).
2024-05-16 Chinese

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.